PubMed HealthSearch

PubMed · 3535376

Trace elements and cardiovascular diseases.

Abstract

Evidence linking marginal intakes of the trace elements, chromium, copper, zinc and selenium, with abnormal lipid metabolism and ultimately cardiovascular diseases is accumulating from both animal and human studies. Chromium supplementation of normal adult men, as well as diabetics, has been reported to increase high density lipoprotein cholesterol and decrease triglycerides and total cholesterol. Subjects with the highest total cholesterol and triglycerides usually respond the most to supplemental chromium. Improvements in lipid metabolism, as well as those in glucose metabolism, appear to be related to improvements in insulin efficiency due likely to increased receptor number. Animal studies also indicate that improvements in serum cholesterol, aortic lipids and plaque formations due to supplemental chromium are associated with decreased circulating insulin. Insufficient dietary copper also leads to elevated lipid levels and impaired heart function. Animal studies indicate an obvious degradation of the heart muscles. Zinc appears to function in cardiovascular diseases primarily via its antagonism with copper. Selenium may also affect cardiovascular diseases since selenium is postulated to be involved in platelet aggregation. These data demonstrate that the trace elements, chromium, copper, and selenium, have beneficial effects on risk factors associated with cardiovascular diseases suggesting that a decreased risk of cardiovascular disease may be achieved by adequate intake of trace elements.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R A Anderson. 1986. Trace elements and cardiovascular diseases.. https://doi.org/10.1111/j.1600-0773.1986.tb02771.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Epidemic of cardiovascular diseases in patients undergoing chronic hemodialysis; closer attention needs to be paid to volume expansion].

The very high mortality of patients on chronic haemodialysis treatment is mainly due to cardiovascular complications. Despite the fact that some dialysis centres report much better survival by adhering to the long-known principle of volume control, investigators and advisory committees all over the world define 'adequate dialysis' exclusively in terms of removal of 'toxic factors'. Volume expansion leads to hypertension, cardiac dilatation and cardiac failure through a clear pathophysiological sequence. By giving more responsibility to dialysis nurses patients may be helped to regain their 'dry weight'.

Cardiovascular Diseases

[Cardiovascular diseases in dialysis patients].

Cardiovascular morbidity and mortality are higher among dialysis patients than among the general population. The cardiovascular problems often exist before the start of dialysis. Their pathogenesis is multifactorial in dialysis patients also. The prevalence of left ventricular hypertrophy is strongly increased. Adequate therapy may lead to partial remission. Cardiac ischaemia is frequent among dialysis patients and may occur without severe coronary artery disease. The prognosis of myocardial infarction in dialysis patients is poorer than in the general population. There is no proven difference between the various dialysis techniques regarding cardiovascular morbidity and mortality, while kidney transplantation may have a beneficial effect. Early diagnosis and treatment aimed at risk factors for cardiovascular disease are indicated.

Cardiovascular Diseases